Tildrakizumab: Additional Phase III data

Pooled data from the double-blind, international Phase III reSURFACE 1 (MK-3222-010) and reSURFACE 2 (MK-3222-011) trials in about 1,862 patients with moderate to severe plaque psoriasis showed that 100 and 200 mg subcutaneous tildrakizumab given at weeks 0 and 4 then every 12 weeks led to PASI 75 response rates of 63% (64% in reSURFACE 1 and 61% in reSURFACE 2) and 64%, respectively, at week 12 and 77% (80% in reSURFACE 1 and 74% in reSURFACE 2) and 78% at week 28. Additionally, low- and high-dose tildrakizumab led to PASI 90 response rates of 37% and 36%, respectively, at week 12 and 54% and 59%, respectively, at week 28. PASI 100 response rates were 13% for both doses of tildrakizumab at week 12 and 24% and 30%, respectively, at week 28. Furthermore, low- and high-dose tildrakizumab led to PGA scores of clear or minimal in 57% and 59% of patients, respectively, at week 12 and 66% and 69% of patients, respectively, at week 28. Data were presented at the European Academy of Dermatology and Venereology meeting in Vienna. ...